Frailty signals in older users of GLP-1 obesity drugs, while rare, warrant attention Frailty conditions in older GLP-1 users are linked with relatively high risks of adverse outcomes Study underscores ...
July 14 (Reuters) - Potential signs of frailty in older adults taking Eli Lilly’s GLP-1 obesity drug Zepbound may signal relatively high risks for adverse outcomes, according to a large study that ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results